Therapeutic drug monitoring enables safe and effective lenalidomide therapy in patients with multiple myeloma on hemodialysis.
Department of Hematology, Nephrology, and Rheumatology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita City, Akita, 010-8543, Japan. naotot@doc.med.akita-u.ac.jp.
Takahiro
T
Kobayashi
Department of Pharmacy, Akita University Hospital, Akita, Japan.
Takenori
T
Niioka
Department of Pharmacy, Akita University Hospital, Akita, Japan.
Masatomo
M
Miura
Department of Hematology, Nephrology, and Rheumatology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita City, Akita, 010-8543, Japan.
Naoto
N
Takahashi
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000097:blood* / Q000627:therapeutic use; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000175:diagnosis / Q000628:therapy*; D006435:Renal Dialysis / Q000639:trends; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D013792:Thalidomide; D000077269:Lenalidomide